Few Americans discuss dementia risk reduction with a doctor because conversations about brain health have not yet become a routine part of medical care, despite strong patient interest. In a 2026 survey, only 11% of U.S. adults age 40 and older said they had discussed ways to reduce their risk of Alzheimer’s disease or other dementias with a physician, while 14% had discussed maintaining brain health. For example, a 55-year-old may routinely review blood pressure, vaccines and cholesterol at an annual visit without anyone connecting those topics to long-term cognitive health.
The survey does not establish why these conversations are uncommon. The Alzheimer’s Association report suggests that limited public awareness and the absence of established clinical guidance may contribute, but those are possible explanations rather than proven causes. It is also important to describe the result precisely: the survey measured discussions about ways to reduce risk, not whether patients received a formal dementia-risk assessment. The striking part is the mismatch between reported practice and public preference. Sixty-six percent of respondents preferred to learn about brain health from a health-care provider, and 86% wanted that information included in routine care, according to the Alzheimer’s Association’s 2026 Alzheimer's Disease Facts and Figures.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the 2026 brain-health survey report — Verify the survey’s methods, population, and reported rates of clinician discussion.
- Review CDC dementia-risk reduction guidance — Use CDC’s modifiable-risk-factor guidance to prepare questions for a health-care visit.
Table of Contents
- Why Do Few Americans Discuss Dementia Risk With a Doctor?
- The Brain Health Knowledge Gap Behind the Discussion Gap
- What Modifiable Dementia Risk Really Means
- How to Start a Brain Health Conversation During Routine Care
- What the U.S. POINTER Trial Can and Cannot Show
- Why Prevention Advice Should Not Be Confused With Alzheimer’s Treatment
- What to Bring to a Dementia-Risk Discussion
- Frequently Asked Questions
Why Do Few Americans Discuss Dementia Risk With a Doctor?
The findings come from a survey of 3,829 U.S. adults age 40 and older conducted from December 29, 2025, through January 13, 2026. Researchers used NORC’s probability-based AmeriSpeak Panel, oversampled several racial and ethnic groups, and weighted the results to Census criteria. The survey was offered in English, either online or by telephone. Those methods support estimates about the surveyed population, but they do not make the findings universal.
Adults under 40 were not included, and an English-only survey may not fully represent the experiences of people who prefer another language. Self-reported conversations can also be remembered differently: one patient may count advice to exercise as a brain-health discussion, while another may not unless the doctor explicitly mentions Alzheimer’s disease. The wording matters as much as the percentages. Saying that only 11% received a “dementia-risk assessment” would go beyond what was measured. Respondents were asked about discussing ways to reduce risk, a broader and less formal interaction that might take place during a wellness visit, diabetes appointment or medication review.
The Brain Health Knowledge Gap Behind the Discussion Gap
Americans appear to place a high value on cognitive well-being without necessarily knowing how to protect it. Ninety-nine percent rated brain health as at least as important as physical health, yet only 9% said they knew “a lot” about maintaining it, according to the Alzheimer’s Association’s 2026 report on brain health. The survey also found a difference between general belief and specific risk understanding. Seventy-five percent considered lifestyle behaviors very important to brain health, but only 46% strongly connected those behaviors with a lower risk of Alzheimer’s disease or other dementias.
Someone may believe walking improves mood and energy, for example, without realizing that physical activity can also be part of a broader discussion about cognitive risk. Awareness alone cannot explain the low discussion rate. The survey did not test doctors’ schedules, reimbursement policies, competing medical priorities, patient reluctance or the availability of local services. The report’s suggestions about limited awareness and missing clinical guidance are plausible interpretations, not evidence that either factor caused an individual appointment to omit brain health.
What Modifiable Dementia Risk Really Means
The Centers for Disease Control and Prevention identifies several potentially modifiable dementia risk factors, including physical inactivity, uncontrolled diabetes, high blood pressure, hearing loss, tobacco use and alcohol use. These subjects already arise in primary care, creating practical opportunities to connect cardiovascular, metabolic and sensory health with the brain. For example, a patient with persistent high blood pressure and untreated hearing loss could ask whether improving blood-pressure control and obtaining a hearing evaluation should be part of a personalized brain-health plan.
A clinician can also review smoking, alcohol consumption, exercise, sleep, medications and diabetes management while accounting for the patient’s health conditions and physical abilities. “Modifiable” does not mean that dementia is always preventable. Age, genetics and other factors remain important, and a person can follow health recommendations yet still develop cognitive impairment. Risk reduction changes probabilities across populations; it does not provide an individual guarantee or justify blaming people who develop dementia.
How to Start a Brain Health Conversation During Routine Care
Patients do not need to wait for memory symptoms to ask about brain health. A useful opening is specific: “Given my blood pressure, hearing and family history, which factors should we address first to support my long-term cognitive health?” Bringing a current medication list, recent test results and notes about family history can help the clinician distinguish general wellness advice from priorities relevant to that patient. There is a tradeoff between breadth and depth during a short appointment. Asking a doctor to cover every possible dementia risk may produce only general advice, while choosing one or two concerns can lead to concrete next steps.
A patient with diabetes might focus on glucose and blood-pressure control; someone struggling to hear conversations might request a hearing assessment rather than treating withdrawal from social settings as an unavoidable part of aging. New or worsening cognitive symptoms require a different conversation from preventive counseling. Repeatedly getting lost, struggling with familiar financial tasks or experiencing changes that disrupt daily life may warrant a clinical evaluation. A risk-reduction discussion cannot substitute for investigating symptoms, medication effects, depression, sleep disorders, vitamin deficiencies or other potentially contributing conditions.
What the U.S. POINTER Trial Can and Cannot Show
The U.S. POINTER randomized clinical trial offers evidence about structured lifestyle support, but it did not prove that dementia can be prevented. Among 2,111 adults considered at risk, a structured program produced a statistically greater improvement in global cognition over two years than a self-guided program. The difference in annual change was 0.029 standard deviations, with a 95% confidence interval of 0.008 to 0.050 and a P value of .008, according to the trial published in JAMA on July 28, 2025. The structured and self-guided programs provide a useful comparison: both involved lifestyle change, but the structured approach offered greater organization and support.
Even so, the size and long-term clinical meaning of the difference remain uncertain. The authors stated that longer follow-up is needed to assess clinical relevance and whether the effects are sustainable. Generalization is also limited by who participated. Participants were ages 60 to 79, were sedentary, had a suboptimal MIND diet and met at least two additional risk criteria; people with cognitive impairment were excluded. The results therefore cannot establish effects for all Americans, for people already experiencing cognitive impairment or for dementia incidence itself. Serious and non-serious adverse events were numerically fewer in the structured group, but this was a lifestyle trial with independent safety monitoring—not a drug-safety result or an FDA approval.
Why Prevention Advice Should Not Be Confused With Alzheimer’s Treatment
Risk-reduction counseling and treatment for diagnosed Alzheimer’s disease are not interchangeable. The FDA granted traditional approval to Leqembi on July 6, 2023, for treating adults with Alzheimer’s disease, with treatment initiated in the mild cognitive impairment or mild-dementia stages and after confirmation of amyloid pathology. It is not approved to prevent dementia in asymptomatic people.
Leqembi also carries risks that do not apply to ordinary lifestyle counseling. The FDA warns about amyloid-related imaging abnormalities, or ARIA, including potentially serious brain swelling and bleeding, and advises APOE ε4 testing to help inform risk. For example, a healthy person concerned only because a parent had Alzheimer’s would not meet the drug’s approved use merely on the basis of family history.
What to Bring to a Dementia-Risk Discussion
A focused appointment can begin with a written record of blood-pressure readings, diabetes measures if applicable, tobacco and alcohol use, typical physical activity, hearing concerns, sleep problems, medications and relevant family history. A patient might ask, “Which of these factors is most important for me to address, and what measurable goal should we review at my next visit?” Family observations can be useful when symptoms are already present, provided the patient agrees to include them. A spouse might report that the patient has missed several bill payments or repeated the same question within an hour—details more clinically useful than saying only that the person seems forgetful.
Frequently Asked Questions
Did the 2026 survey find that only 11% of all Americans discussed dementia risk with a doctor?
No. The finding applies to surveyed U.S. adults age 40 and older. Eleven percent reported discussing ways to reduce the risk of Alzheimer’s disease or other dementias with a physician.
Did the survey explain why these discussions are rare?
It did not establish a causal explanation. The report suggested that limited awareness and the absence of established clinical guidance may contribute, but it did not prove that either caused the low discussion rate.
Can lifestyle changes prevent dementia?
They may help reduce risk, but they cannot guarantee prevention for an individual. Managing factors such as physical inactivity, high blood pressure, uncontrolled diabetes, hearing loss, tobacco use and alcohol use can support health while dementia risk remains influenced by age, genetics and other factors.
Did U.S. POINTER prove that its program prevents Alzheimer’s disease?
No. The trial found a statistically greater improvement in global cognition with a structured lifestyle program than with a self-guided program over two years. It did not demonstrate prevention of dementia, and longer follow-up is needed.
Is Leqembi approved for people who have no symptoms but want to prevent dementia?
No. Its approved use is treatment of Alzheimer’s disease initiated during mild cognitive impairment or mild dementia in patients with confirmed amyloid pathology.
